NCT03136497 - A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

November 9, 2020

Study Completion Date

November 9, 2020

Conditions

Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

400mg ABT-199

Oral dose daily until disease progression

DRUG

Ibrutinib

Oral dose daily until disease progression

DRUG

Rituximab

Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1

DRUG

800mg ABT-199

Oral dose daily until disease progression

Trial Locations (1)

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack